Alvotech begins trading on Nasdaq Stockholm
Biotechnology company Alvotech commenced trading of its Swedish Depositary Receipts (SDRs) on Nasdaq Stockholm today. The company raised approximately SEK 39 million in the offering.
Reykjavik, Iceland and Stockholm, Sweden – May 19, 2025 – Biotechnology firm Alvotech began trading its Swedish Depositary Receipts (SDRs) on Nasdaq Stockholm today. This listing adds to the company's existing presence on Nasdaq US and Nasdaq Iceland.
The offering of SDRs attracted significant interest from the Swedish public and was oversubscribed multiple times. The offering raised gross proceeds of approximately SEK 39 million (approximately EUR 3.4 million). The price per SDR was set at SEK 87.51, reflecting a discount to the volume-weighted average price of the company's shares on Nasdaq Iceland.
Alvotech specializes in the development and manufacturing of biosimilar medicines for patients worldwide. CEO Róbert Wessman stated that the Nasdaq Stockholm listing aims to improve access for investors in Nordic and European markets and enhance share liquidity.
The company is also strengthening its research and development capabilities in Sweden through the acquisition of Xbrane Biopharma AB's R&D operations at the Karolinska life science hub. This move is expected to expand Alvotech's access to experienced life science professionals and solidify its position within the Swedish biotech sector.